Palantir raises its 2026 revenue outlook as Q3 sales surge 96% on AI demand, fueled by U.S. commercial growth, stronger margins and expanding customer spending.
Palantir's 96% revenue growth, rising earnings estimates and strong cash flow support its AI expansion, but a steep valuation raises questions about holding the stock.
TSM's $2 billion deal with GlobalFoundries could ease AI packaging bottlenecks and expand CoWoS capacity, but benefits hinge on a successful 2028 ramp.
Japan's unexpected Q3 GDP contraction raises questions for ETF investors, but resilient corporate investment growth offers reasons to watch the market.
Investors seeking nuclear energy growth opportunities may consider NXE, CW and CEG, given their expertise in uranium, nuclear technology and power generation.
Cadiz (CDZI) delivered earnings and revenue surprises of -14.29% and -52.65%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems (RPID) delivered earnings and revenue surprises of -10.00% and +0.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Gerdau's valuation discount, stronger North American earnings and robust cash flow support its appeal, but Brazilian oversupply and project execution risks remain.
Gerdau's 12.4% decline contrasts with rising earnings estimates, as North American strength, Brazil's steel market pressures and project execution shape its recovery outlook.
TSM's AI-driven growth and rising earnings bolster its outlook, but heavy capital spending, overseas fab costs and mixed valuations call for selective buying.